-
Something wrong with this record ?
Plasma bio-adrenomedullin is a marker of acute heart failure severity in patients with acute coronary syndrome
M. Arrigo, J. Parenica, E. Ganovska, M. Pavlusova, A. Mebazaa,
Language English Country Ireland
Document type Journal Article
NLK
Directory of Open Access Journals
from 2013
Free Medical Journals
from 2015
PubMed Central
from 2014
Europe PubMed Central
from 2014 to 2020
Open Access Digital Library
from 2013-01-01
Open Access Digital Library
from 2014-12-01
ROAD: Directory of Open Access Scholarly Resources
from 2015
- Publication type
- Journal Article MeSH
Background: The assessment of acute heart failure (AHF) in patients with acute coronary syndrome (ACS) is challenging. This study tested whether measuring plasma adrenomedullin in patients admitted for ACS provides valuable information regarding the presence of AHF at admission or its occurrence during hospitalization. Methods and results: The study population consisted of 927 prospectively enrolled patients with ACS. Blood samples for the measurement of plasma bio-adrenomedullin (bio-ADM) were collected at admission. Patients with alveolar pulmonary edema and interstitial pulmonary edema on chest radiography at admission had stepwise higher plasma concentrations of bio-ADM compared to patients with no or mild pulmonary congestion: 54.3 ± 10.6 vs. 27.6 ± 2.1 vs. 22.5 ± 0.7 ng/L, overall P < 0.001. Patients with ACS complicated by AHF during the index hospitalization displayed higher plasma bio-ADM concentrations at admission compared to patients without AHF (33.8 ± 2.7 vs. 21.8 ± 0.7, P < 0.001): the higher the severity of AHF, the higher plasma bio-ADM concentrations at admission. Patients with cardiogenic shock displayed the highest values. Accordingly, bio-ADM concentrations at admission were associated with a higher risk of occurrence of AHF during index hospitalization (odds ratio 1.018, 95% confidence interval 1.011-1.026, P < 0.001). Conclusions: Plasma adrenomedullin is a marker associated with AHF severity in patients with ACS.
Department of Cardiology University Hospital Zurich Zurich Switzerland
Department of Internal Medicine and Cardiology University Hospital Brno Brno Czech Republic
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19013219
- 003
- CZ-PrNML
- 005
- 20190426132920.0
- 007
- ta
- 008
- 190405s2019 ie f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.ijcha.2019.02.011 $2 doi
- 035 __
- $a (PubMed)30906846
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ie
- 100 1_
- $a Arrigo, Mattia $u Department of Cardiology, - University Hospital Zurich, Zurich, Switzerland.
- 245 10
- $a Plasma bio-adrenomedullin is a marker of acute heart failure severity in patients with acute coronary syndrome / $c M. Arrigo, J. Parenica, E. Ganovska, M. Pavlusova, A. Mebazaa,
- 520 9_
- $a Background: The assessment of acute heart failure (AHF) in patients with acute coronary syndrome (ACS) is challenging. This study tested whether measuring plasma adrenomedullin in patients admitted for ACS provides valuable information regarding the presence of AHF at admission or its occurrence during hospitalization. Methods and results: The study population consisted of 927 prospectively enrolled patients with ACS. Blood samples for the measurement of plasma bio-adrenomedullin (bio-ADM) were collected at admission. Patients with alveolar pulmonary edema and interstitial pulmonary edema on chest radiography at admission had stepwise higher plasma concentrations of bio-ADM compared to patients with no or mild pulmonary congestion: 54.3 ± 10.6 vs. 27.6 ± 2.1 vs. 22.5 ± 0.7 ng/L, overall P < 0.001. Patients with ACS complicated by AHF during the index hospitalization displayed higher plasma bio-ADM concentrations at admission compared to patients without AHF (33.8 ± 2.7 vs. 21.8 ± 0.7, P < 0.001): the higher the severity of AHF, the higher plasma bio-ADM concentrations at admission. Patients with cardiogenic shock displayed the highest values. Accordingly, bio-ADM concentrations at admission were associated with a higher risk of occurrence of AHF during index hospitalization (odds ratio 1.018, 95% confidence interval 1.011-1.026, P < 0.001). Conclusions: Plasma adrenomedullin is a marker associated with AHF severity in patients with ACS.
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Parenica, Jiri $u Department of Internal Medicine and Cardiology, - University Hospital Brno, Brno, Czech Republic. Faculty of Medicine, Masaryk University, Brno, Czech Republic.
- 700 1_
- $a Ganovska, Eva $u Department of Internal Medicine and Cardiology, - University Hospital Brno, Brno, Czech Republic.
- 700 1_
- $a Pavlusova, Marie $u Department of Internal Medicine and Cardiology, - University Hospital Brno, Brno, Czech Republic.
- 700 1_
- $a Mebazaa, Alexandre $u INSERM UMR-S 942, Université Paris Diderot - PRES Sorbonne Paris Cité, Department of Anesthesiology and Critical Care Medicine - AP-HP Saint Louis and Lariboisière University Hospitals, Paris, France.
- 773 0_
- $w MED00198717 $t International journal of cardiology. Heart & vasculature $x 2352-9067 $g Roč. 22, č. - (2019), s. 174-176
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/30906846 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20190405 $b ABA008
- 991 __
- $a 20190426132957 $b ABA008
- 999 __
- $a ind $b bmc $g 1392529 $s 1051524
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 22 $c - $d 174-176 $e 20190309 $i 2352-9067 $m International journal of cardiology Heart & vasculature $n Int J Cardiol Heart Vasc $x MED00198717
- LZP __
- $a Pubmed-20190405